HIV vax researchers ponder best R&D strategies

Emboldened by a glimpse of the potential of a new HIV vaccine, more than 1,000 researchers from around the world are gathering in Atlanta this week to share their thoughts on the best strategies for finally finding a shot which can guard against the lethal virus. "Over the past year, scientists have identified neutralizing antibodies against HIV, which are a fundamental building block for developing a vaccine," Mitchell Warren, executive director of the Aids Vaccine Advocacy Coalition, tells the Guardian. Story